BRAF and colorectal carcinoma: To search for phosphatases whose knockdown induces sensitivity to BRAF inhibition, Prahallad and colleagues performed, in BRAF-mutant CRC cells treated with vemurafenib, an shRNA-screen targeting 298 phosphatases or phosphatase-related genes; PTPN11 was identified as a central node in intrinsic and acquired resistance to BRAFV600E inhibition [145].